# US 2015/0105441 A1 · Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105441 A1
- Document ID: US20150105441A1
- Status: Published application
- Kind: A1
- Application number: 14/385,211
- Filed: 2013-03-13
- Published: 2015-04-16
- Earliest claimed: 2012-03-14
- Assignees: University of Central Florida Research Foundation, Inc.
- Applicants: University of Central Florida Research Foundation, Inc.
- Inventors: Cristina Fernandez-Valle
- Web page: https://patentgrep.com/patent/US20150105441A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/38: having sulfur as a ring hetero atom
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5014: {for testing toxicity}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5058: {Neurological cells}
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- C12N 2310/11: Antisense
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LIMK modulating agent. Also disclosed are compounds newly identified to be inhibitors of Merlin-null Schwann cell proliferation and/or survival.

## Claims

### Claim at position 1

1-47. (canceled)

### Claim 48

A method for treating a neurofibromatosis in a subject, the method comprising administering to the subject an effective amount of a LIMK modulating agent, prodrugs, analogs, derivatives, metabolites, and/or pharmaceutically acceptable salts thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the neurofibromatosis is type 1 Neurofibromatosis (NF1).

### Claim 50 (depends on 48)

The method of claim 48, wherein the neurofibromatosis is type 2 Neurofibromatosis (NF2).

### Claim 51 (depends on 48)

The method of claim 48, wherein the neurofibromatosis is Schwannomatosis.

### Claim 52 (depends on 48)

The method of claim 48, wherein the neurofibromatosis includes sporadic Schwannoma in a non-NF patient

### Claim 53 (depends on 48)

The method of claim 48, wherein the LIMK modulating agent is selected from the group consisting of a ribozyme, an interfering molecule, a peptide, a small molecule, an antibody targeted to LIMK, and combinations thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the LIMK modulating agent comprises BMS-5 or prodrug, analog, derivative, metabolite, and/or pharmaceutically acceptable salt thereof.

### Claim 55 (depends on 48)

The method of claim 48, wherein the LIMK modulating agent comprises an interfering molecule, and wherein the interfering molecule comprises a member selected from the group consisting of a phosphothioate morpholino oligomer (PMO), miRNA, siRNA, methylated siRNA, treated siRNAs, shRNA, antisense RNA, a dicer-substrate 27-mer duplex, and combinations thereof.

### Claim 56 (depends on 48)

The method of claim 48, wherein the subject exhibits a symptom of a neurofibromatosis.

### Claim 57 (depends on 56)

The method of claim 56, wherein the symptom comprises a presence of multiple coffee-colored patches on a skin of the subject, hearing loss or disequilibrium, or a combination thereof.

### Claim 58 (depends on 48)

The method of claim 48, wherein the LIMK modulating agent comprises BMS-5, or prodrug, analog, derivative, metabolite, and/or pharmaceutically acceptable salt thereof.

### Claim 59

A method of inhibiting Schwann cell proliferation in a subject comprising administering an effective amount of an LIMK modulating agent, or prodrug, analog, derivative, metabolite, and/or pharmaceutically acceptable salt thereof, to the subject to inhibit the expression or action of LIMK.

### Claim 60 (depends on 59)

The method of claim 59, wherein the LIMK modulating agent is selected from the group consisting of a ribozyme, an interfering molecule, a peptide, a small molecule, or an antibody targeted to LIMK.

### Claim 61 (depends on 59)

The method of claim 59, wherein the LIMK modulating agent comprises BMS-5, or prodrug, analog, derivative, metabolite, and/or pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 59)

The method of claim 59, wherein the LIMK modulating agent comprises an interfering molecule.

### Claim 63 (depends on 62)

The method of claim 62, wherein the interfering molecule comprises a member selected from the group consisting of a phosphothioate morpholino oligomer (PMO), miRNA, siRNA, methylated siRNA, treated siRNAs, shRNA, antisense RNA, a dicer-substrate 27-mer duplex, and any combination thereof.

### Claim 64 (depends on 59)

The method of claim 59, wherein the LIMK modulating agent comprises TAK165; or prodrug, analog, derivative, metabolite, and/or pharmaceutically acceptable salt thereof.

### Claim 65

A method of screening for compounds capable of affecting a neurofibromatosis, said method comprising
contacting at least one LIMK modulating test compound with at least one NF2-inactivated cell; and
detecting for growth of or cytotoxicity to said at least one NF2-inactivated cell; wherein a test compound that modulates growth of or cytotoxicity to said at least one NF2-inactivated cell is identified as a potential LIMK modulating agent;
wherein said method is set up in a high throughput format, wherein said at least one NF2-inactivated cell comprises a multiplicity of cell samples separated and disposed in individual wells in a multi-well plate.

### Claim 66 (depends on 65)

The method of claim 65, wherein said multi-well plate comprises a high transmittance portion through which cells present in said wells are optically observable in an area of observation; and said method, optionally, further comprises implementation of an optical detector configured to detect light emanating from said wells through said high transmittance portion; and a data processing unit configured to store data indicative of light intensity detected by said optical detector and corresponding to modulation of at least some of said cells, wherein said cells are NF2-inactivated Schwan cells.

### Claim 67 (depends on 65)

The method of claim 65, wherein said multi-well plate comprises up to 96 wells, up to 384 wells, or up to 1536 wells.
